Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma …

Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …

Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally …

Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor recommended for the treatment
of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing …

Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

This is a comment on" Atezolizumab in patients with locally advanced and metastatic
urothelial carcinoma who have progressed following treatment with platinum-based …

Background Patients with metastatic urothelial carcinoma (mUC) who progress after
platinum-based chemotherapy have had few treatment options and uniformly poor …

Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …